Recent Advances in Neonatal Diabetes.

Diabetes Metab Syndr Obes

Division of Pediatric Endocrinology and Metabolism, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.

Published: February 2020

AI Article Synopsis

  • Neonatal diabetes mellitus (DM) is characterized by high blood sugar levels occurring within the first six months of life, potentially up to 12 months.
  • Over 80% of affected children have a gene mutation that impacts insulin production or pancreatic function.
  • Genetic testing is crucial for determining the type of treatment, with specific mutations allowing for oral sulfonylurea therapy, while other mutations necessitate insulin treatment.

Article Abstract

Neonatal diabetes mellitus (DM) is defined by the onset of persistent hyperglycemia within the first six months of life but may present up to 12 months of life. A gene mutation affecting pancreatic beta cells or synthesis/secretion of insulin is present in more than 80% of the children with neonatal diabetes. Neonatal DM can be transient, permanent, or be a component of a syndrome. Genetic testing is important as a specific genetic mutation can significantly alter the treatment and outcome. Patients with mutations of either KCNJ11 or ABCC8 that encode subunits of the K channel gene mutation can be managed with sulfonylurea oral therapy while patients with other genetic mutations require insulin treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024796PMC
http://dx.doi.org/10.2147/DMSO.S198932DOI Listing

Publication Analysis

Top Keywords

neonatal diabetes
12
diabetes neonatal
8
months life
8
gene mutation
8
advances neonatal
4
diabetes mellitus
4
mellitus defined
4
defined onset
4
onset persistent
4
persistent hyperglycemia
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!